Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

NCT07446452 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

HER2-low Breast Cancer

Interventions

DRUG: Disitamab Vedotin (RC48)
DRUG: Bevacizumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]